Stillwater Investment Management LLC Has $2.38 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)
Stillwater Investment Management LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 1.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 72,775 shares of the biopharmaceutical company’s stock after purchasing an additional 1,380 shares during the quarter. Stillwater Investment Management LLC’s holdings in Pfizer were worth $2,380,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Reik & CO. LLC boosted its stake in Pfizer by 1.4% during the 1st quarter. Reik & CO. LLC now owns 19,160 shares of the biopharmaceutical company’s stock valued at $625,000 after purchasing an additional 265 shares during the last quarter. Prospera Financial Services Inc boosted its stake in shares of Pfizer by 0.5% in the 4th quarter. Prospera Financial Services Inc now owns 51,834 shares of the biopharmaceutical company’s stock worth $2,031,000 after buying an additional 274 shares during the last quarter. Windsor Capital Management LLC boosted its stake in shares of Pfizer by 1.6% in the 1st quarter. Windsor Capital Management LLC now owns 17,991 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 276 shares during the last quarter. GYL Financial Synergies LLC boosted its stake in shares of Pfizer by 0.9% in the 1st quarter. GYL Financial Synergies LLC now owns 30,718 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 283 shares during the last quarter. Finally, Gilbert & Cook Inc. boosted its stake in shares of Pfizer by 3.0% in the 1st quarter. Gilbert & Cook Inc. now owns 9,794 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 285 shares during the last quarter. 70.28% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Jennifer B. Damico sold 2,181 shares of Pfizer stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $38.35, for a total value of $83,641.35. Following the sale, the senior vice president now directly owns 9,647 shares of the company’s stock, valued at $369,962.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Douglas M. Lankler sold 65,000 shares of Pfizer stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $37.85, for a total value of $2,460,250.00. Following the completion of the sale, the executive vice president now directly owns 135,375 shares in the company, valued at $5,123,943.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 69,362 shares of company stock worth $2,622,691. Insiders own 0.08% of the company’s stock.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.09. The business had revenue of $12.03 billion for the quarter, compared to analysts’ expectations of $11.38 billion. Pfizer had a return on equity of 25.76% and a net margin of 31.17%. The business’s quarterly revenue was down 8.3% on a year-over-year basis. During the same period last year, the firm earned $0.85 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.88 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 31st will be issued a dividend of $0.38 per share. The ex-dividend date of this dividend is Thursday, July 30th. This represents a $1.52 dividend on an annualized basis and a yield of 4.40%. Pfizer’s dividend payout ratio is presently 51.53%.
A number of research firms have recently issued reports on PFE. Piper Sandler raised their price target on Pfizer from $18.50 to $24.00 in a research note on Friday, June 26th. SVB Leerink began coverage on Pfizer in a research note on Tuesday, June 16th. They issued a “market perform” rating and a $40.00 price target on the stock. Morgan Stanley dropped their price target on Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 2nd. Barclays dropped their price target on Pfizer from $37.00 to $35.00 in a research note on Monday, June 1st. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $53.00 price target on shares of Pfizer in a research note on Thursday, March 19th. Ten research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $38.72.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: What is a growth and income fund?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.